Evaluation of anti-prion activity of congo red and its derivatives in experimentally infected hamsters
- PMID: 15344846
- DOI: 10.1055/s-0031-1296992
Evaluation of anti-prion activity of congo red and its derivatives in experimentally infected hamsters
Abstract
Among transmissible spongiform encephalopathies (TSE), particularly dreadful are the bovine spongiform encephalopathy (BSE), because of its epidemic character, and the new variant of Creutzfeldt-lakob disease (vCJD) in man, possibly related to BSE prion, through the intake of infected food. To treat TSE, many potentially therapeutic agents have been tested: some of them, among which is Congo Red (CAS 573-58-0, CR), delayed the onset of symptoms in scrapie-infected rodents, and some CR derivatives proved to be effective in vitro. The capacity of a synthesized CR derivative (CR-A) and of the aromatic central benzidine rings of CR (CR-B) to abrogate scrapie-induced disease in experimentally infected hamsters was assayed. CR, used as reference substance, administered i.c. after pre-incubation with the scrapie inoculum, was strongly effective in slowing the progression of the infection, while both CR-A and CR-B, administered alone or together, were not effective. Both CR-A and CR, when administered by subcutaneous route in i.c. scrapie-infected animals. prolonged the survival time in comparison to controls; CR-B was not effective. Moreover, both CR and CR-A were very effective in prolonging the survival time of i.p. scrapie-infected hamsters. The hypothesis of possible different mechanisms of interaction between CR or CR-A and the scrapie agent related to the chemical structures of the molecules is discussed.
Similar articles
-
In vitro evaluation of the anti-prionic activity of newly synthesized congo red derivatives.Arzneimittelforschung. 2003;53(12):875-88. doi: 10.1055/s-0031-1299845. Arzneimittelforschung. 2003. PMID: 14750496
-
Screening Congo Red and its analogues for their ability to prevent the formation of PrP-res in scrapie-infected cells.J Gen Virol. 2000 Apr;81(Pt 4):1155-64. doi: 10.1099/0022-1317-81-4-1155. J Gen Virol. 2000. PMID: 10725446
-
Preparation of soluble infectious samples from scrapie-infected brain: a new tool to study the clearance of transmissible spongiform encephalopathy agents during plasma fractionation.Transfusion. 2006 Apr;46(4):652-8. doi: 10.1111/j.1537-2995.2006.00763.x. Transfusion. 2006. PMID: 16584444
-
Prion encephalopathies of animals and humans.Dev Biol Stand. 1993;80:31-44. Dev Biol Stand. 1993. PMID: 8270114 Review.
-
The use of non-prion biomarkers for the diagnosis of Transmissible Spongiform Encephalopathies in the live animal.Vet Res. 2005 Sep-Dec;36(5-6):665-83. doi: 10.1051/vetres:2005028. Vet Res. 2005. PMID: 16120244 Review.
Cited by
-
Therapeutic activity of inhibition of the soluble epoxide hydrolase in a mouse model of scrapie.Life Sci. 2013 Jun 21;92(23):1145-50. doi: 10.1016/j.lfs.2013.04.014. Epub 2013 May 5. Life Sci. 2013. PMID: 23651659 Free PMC article.
-
Interaction of Avapritinib with Congo Red in Pancreatic Cancer Cells: Molecular Modeling and Biophysical Studies.Int J Mol Sci. 2025 Feb 25;26(5):1980. doi: 10.3390/ijms26051980. Int J Mol Sci. 2025. PMID: 40076604 Free PMC article.
-
Styryl-based and tricyclic compounds as potential anti-prion agents.PLoS One. 2011;6(9):e24844. doi: 10.1371/journal.pone.0024844. Epub 2011 Sep 13. PLoS One. 2011. PMID: 21931860 Free PMC article.
-
Recent advances in prion chemotherapeutics.Infect Disord Drug Targets. 2009 Feb;9(1):81-91. doi: 10.2174/1871526510909010081. Infect Disord Drug Targets. 2009. PMID: 19200018 Free PMC article. Review.
-
Prion therapeutics: Lessons from the past.Prion. 2022 Dec;16(1):265-294. doi: 10.1080/19336896.2022.2153551. Prion. 2022. PMID: 36515657 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources